Search for a trial

A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL)

This study will evaluate the long-term safety and efficacy of atezolizumab in patients with locally advanced or metastatic NSCLC who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy…

CT-controlled advanced navigation techniques for transbronchial pulmonary lesion access; evaluation of augmented fluoroscopy bronchoscopic navigation based diagnostic yield.

Diagnostic yield and navigation accuracy of a combination of commercially available endobronchial navigation and imaging techniques will be evaluated in patients with peripheral pulmonary lesions. Cost-effectiveness and safety will be modelled on…

CT-controlled advanced navigation techniques for transbronchial pulmonary lesion access; evaluation of electromagnetic navigation based diagnostic yield.

Diagnostic yield and navigation accuracy of a combination of commercially available endobronchial navigation and imaging techniques will be evaluated in patients with peripheral pulmonary lesions. Cost-effectiveness and safety will be modelled on…

A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WELL DIFFERENTIATED, METASTATIC AND/OR UNRESECTABLE TYPICAL OR ATYPICAL LUNG NEUROENDOCRINE TUMORS

Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Primary objectives:* Part 1: To evaluate the safety and tolerability and determine the recommended dose(s) of INCB059872 for further study in advancedmalignancies.* Part 2: To further evaluate the safety and tolerability of INCB059872 for further…

A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M

Primary objectiveTo assess the efficacy of the combination of osimertinib and bevacizumab versus osimertinib alone in terms of progression-free survival (PFS) assessed by RECIST 1.1.Secondary Objectives:To compare short and long term clinical…

An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with well-differentiated advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gasteroenteropancreatic neuroendocrine carcinoma (GEP-NEC) who have progressed on prior treatment (CPDR001E2201)

Primary: To estimate the antitumor activity (assessed as overall response rate) of PDR001 as a single agent in patients with non-functional neuro-endocrine tumors (NET).Secondary: To estimate efficacy (duration of response) of PDR001. Safety and…

Tumormarkers in diagnostics and follow up of lungcarcinoma

This study aims to prospectively evaluate the diagnostic properties and clinical value of the protein tumor markers CEA, CA15.3, Cyfra21.1, HE4, NSE, proGRP en SCC and the molecular tumormarkers EGFR, ALK, KRAS and BRAF in diagnosing, and monitoring…

Fully Automated Scan Technique: Optimisation of Scan Timing in chest CT [FAST START trial]

Primary objective:- To evaluate the performance of the FAST software in patients receiving a chest CT with regard to the number of non-diagnostic scans (> 300 HU) in comparison with standard care ('default' delay). Secondary…

Comparing tumour heterogeneity in primary tumour, circulating tumour cells and its metastases

- Comparing the heterogeneity of the original tumour and its metastases.- Comparing the mutations in CTC*s to those of both the original tumour and the metastatic processes.- Assessing whether certain mutations precede the others (so called trunk…

Long term effect of definitive chemoradiotherapy on respiratory function tests in patients with locally advanced (non)-small cell lung carcinoma

The aim of the study is to evaluate the change of lung function at least one year after definitive chemoradiation (concurrent or sequential) or radiotherapy alone in patients with locally advanced (non) small cell lung carcinoma to assess late…

MEDIASTINAL STAGING OF NON SMALL CELL LUNG CANCER BY ENDOBRONCHIAL AND ENDOSCOPIC ULTRASONOGRAPHY WITH OR WITHOUT ADDITIONAL SURGICAL MEDIASTINOSCOPY (MEDIASTrial)

Omitting mediastinoscopy improves cost-effectiveness and cost-utility of NSCLC staging, despite a slightly lower metastatic nodal detection rate.

A Phase 3, randomized, open label study of lorlatinib (PF 06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK positive non small cell lung cancer

This study has been transitioned to CTIS with ID 2023-509169-19-00 check the CTIS register for the current data. To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival…

A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Primary: • Part 1:To evaluate the efficacy of NIR178 and PDR001 combination in patients with selected advanced solid tumors and diffuse large B cell lymphoma (DLBCL). • Part 2: To assess the efficacy of several intermittent dosing schedules of…